| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61f88efcda59d7062a4252ecf6886f58 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5154
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-22034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-572
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-22022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0639 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0784
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 |
| filingDate |
2015-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37765a4bc18f928f18a3456a51b13ceb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09a8339bf5f07ef2c5f252f93c7d709d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d602516f5c5053723e1944d7937b6a1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_935471f82d2f8abf315c5b54e47396d1 |
| publicationDate |
2016-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2016073595-A1 |
| titleOfInvention |
T cells and dendritic cells for polyomavirus therapy |
| abstract |
Disclosed herein are dendritic cells (DCs) expressing one or more polyomavirus antigens. In some examples, these modified DCs are transduced with a viral vector (such as a lenti viral vector) encoding the one or more polyomavirus antigens. The modified DCs are in some examples used to produce polyomavirus antigen-specific T cells. Also disclosed are methods of producing polyomavirus antigen-specific T cells by contacting mononuclear cells with a mixture of peptides from a polyomavirus antigen. The antigen-specific T cells or modified DCs may be administered to a subject to induce or enhance an immune response to polyomavirus in the subject, for example to treat or inhibit polyomavirus infection and/or polyomavirus-associated disease in the subject. Also disclosed herein are methods of making the disclosed modified DCs and polyomavirus antigen-specific T cells. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11293010-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3203237-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11524065-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021511320-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2023201328-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022253957-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019143921-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10821134-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10772914-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11118164-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021014213-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018333435-A1 |
| priorityDate |
2014-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |